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ABSTRACT 
Validation of Prognostic Biomarkers for Overall Survival in Melanoma 
Patients Undergoing Autologous Vaccination 
       Zeynep Özge AYYILDIZ 
M.Sc.in Molecular Biology and Genetics 
Supervisor Assist. Prof. Dr. Ali OSMAY GÜRE 
         April 2014 
 
Malignant Melanoma is deadliest type of skin cancer, seen with low frequency. Lack of 
diagnostic and prognostic markers are important obstacles during early detection and selection 
of appropriate adjuvant therapy for malignant melanoma patients. Upon early diagnosis of 
melanoma in patients with stage IA and IB, the survival rates for 5 to 10 years is above 85% 
based on American Cancer Society statistics. However, with increasing stage and low survival 
rates, selection of appropriate post surgical adjuvant therapy has high impact to increase the 
survival and life quality of patients. Immunotherapy trials targeting malignant melanoma 
(MM) patients have been developing in larger extents in the last 2 decades, considering 
melanoma is the most immugenic cancer type among all cancers. Based on these facts, we 
decided to search for prognostic biomarkers which will guide clinicians to define appropriate 
malignant melanoma patients to apply autologous vaccination as a post surgical adjuvant 
therapy. With the contribution of our collaborator research group, we were able to obtain 28 
primary cell cultures of MM patients with known survival outcomes, and their gene 
expression profiles in Luminex platform. Grounding from the results of Unsupervised 
Survival Analysis Tool (USAT; a software designed to determine prognosis-associated 
mRNAs, developed in our laboratory), we decided to validate the expression profiles of 
prospective prognostic biomarker genes in the primary cell culture samples, with qRT-PCR. 
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Subsequent to elimination of samples determined as being altered in culture over time, and 
thus no longer representing their expression profile, based on Sum of Absolute Rank 
Difference (SARD) analysis, 8 genes validated out of 10 in 21 samples were as follows; CT 
genes (SSX1, MAGEA1), EMT markers (CDX2, CLDN1), DNA repair genes (ERCC1, 
LIG3), transforming growth factor alpha (TGFα), A-kinase anchor protein 13 (AKAP13). 
Previous studies of our laboratory, concerning high immunogenic potential of CT genes in 
cancers, made SSX1 and MAGEA1 our major interest in autologous vaccinated MM patients. 
Our findings suggest that autologous vaccination might increase overall survival especially in 
malignant melanoma patients whose tumors show higher CT gene expression. We show that 
high expression of TGFα can also be used as a prognostic marker for identifying patients who 
will benefit from this treatment.   
Keywords: Malignant Melanoma, Autologous Vaccination, Cancer Testis Genes, TGFα. 
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ÖZET 
Otolog Aşı yapılmış Malign Melanoma hastalarında prognoz ile ilgili 
belirteç onaylaması 
       Zeynep Özge AYYILDIZ 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez Yöneticisi: Yrd. Doç.Dr. Ali OSMAY GÜRE 
   Nisan 2014 
Malign Melanoma, nadir görülen en ölümcül deri kanseri türüdür. Malign melanoma 
hastalarının tanı ve tedavisi için belirteçlerin eksikliği, hastaların erken teşhisi ve hastalar için 
uygun destekleyici tedavi yöntemlerinin seçilmesinin önünde önemli bir engeldir. 
Melanomanın erken teşhis edilmesi takdirde IA ve IB evresindeki hastaların 5-10 yıllık 
hayatta kalma oranları Amerika Kanser Topluğunun istatistiklerine gore  %85’in üzerindedir. 
Bunun yanı sıra,  ilerleyen evre ve düşen hayatta kalma oranları ile birlikte, cerrahi müdahele 
sonrası uygun destekleyici tedavinin seçiminin hastaların hayatta kalma oranlarına ve hayat 
kalitelerin artırılmasına etkisi yüksektir. Melanomanın kanser türleri arasında en immunojenik 
kanser türü olması sebebiyle, malign melanoma hastalarını hedef alan immunoterapi 
denemeleri son 20 yılda daha geniş kapsamlı olarak geliştirilmektedir. Bunlara dayanarak, 
klinisyenlerin cerrahi müdahele sonrası otolog aşı yapılması için uygun malign melanom 
hastalarını belirlemelerinde kullanabilecekleri prognoz ile ilişkili belirteç araştırmaya karar 
verdik. İş birliği içinde olduğumuz araştırma grubunun katkısıyla, 28 malign melanom hastası 
primer hücre kültürü ve Luminex platformunda gen ekspresyon profilerini temin ettik. 
Güdümsüz Sağkalım Analiz Programı (USAT: laboratuarımızda geliştirilmiş sağ kalımla 
ilişkili genleri tespite yarayan bir yazılım) sonuçları temelinde, prognozla ilişkisi muhtemel 
genlerin gen ifade profilerini primer hücre kültürlerinde, qRT-PCR ile onamaya karar verdik. 
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Hücre kültürü sırasında değişen ve dolaysıyla gen ifadeleri Luminex verileriyle örtüşmeyecek 
hale gelmiş hücre kulturlerinin Mutlak Sıra Farkı Toplamı (SARD) analizine dayanarak 
elenmesinden sonra, 21 örnekte çalıştığımız 10 genin doğrulanabilen 8’i; CT genleri (SSX1, 
MAGEA1), epitelyal mezenkimal belirteç genleri (CDX2, CLDN1), DNA onarım genleri 
(ERCC1, LIG3), transforme edici büyüme fakötürü (TGFα), kinaz A taşıyıcı proteini 
(AKAP13) idi. Laboratuarlarımızdaki CT genlerinin kanserlerdeki yüksek immunojenik 
potensiyellerine ait geçmiş çalışmalar, SSX1 ve MAGEA1 genlerini otolog aşılanmış malign 
melanoma hastalarında esas ilgimiz haline getirdi. Sonuçlarımız CT gen ifadesi yüksek olan 
malign melanom hastalarına otolog aşı yapılmasının genel sağkalımı artırmada faydalı 
olduğunu düşündürtüyor. Buna ek olarak, yüksek TGFα ifadesinin de otolog aşılamaya tabi 
tutulacak hastalarda prognozla ilişkili belirteç olduğu anlaşılmaktadır. 
Anahtar kelimeler: Malign Melanom, Otolog Aşılama, Kanser testis genleri, TGFα. 
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1 INTRODUCTION 
1.1 Histology and Anatomy of the Skin  
Skin with total 16% of body weight and 1.8 m² surface areas, is the largest organ of the 
body. Water and electrolyte balance, protections against UV, microorganism, mechanical 
insults or toxic agents are maintained by skin. Skin consists of three structural layers; (1) 
epidermis, (2) dermis, (3) subcutis. Structure of the skin (Figure 1.1) is constant though, 
thickness of it may vary depending on the location.  
               
                    Figure 1.1 General structure of the skin (microscopic cross section) 
Besides keratinocytes, which are the main cell type in epidermis, melanocytes function 
to (1) form a connection between  neighbouring keratinocytes in stratum basale, (2) produce 
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and (3) store melanin in their melanosome. Melanin is transferred to keratinocytes, where they 
reside in granules, will be beneficial against harmfull effects of UV.
1
  
1.2 Melanocyte development of the Skin 
Skin melanocytes are originated from the neural crest cells (NCC) resides in the 
embryonic germlayer ectoderm. Multipotent properties of NCCs are lost gradually in 
developmental process and they become lineage restricted cells.
2, 3
 Lineage restriction counts 
on the location of NCCs. Traditionally, NCCs located in dorsal trunk region give rise to 
epidermal melanocytes migrating dorsa-laterally.
4
 However, NCCs travelling ventrally can be 
maintained as multipotent cells which will turn into myelin sheats or melanocytes.
5
 
Embryonic cutaneous innervation hosts invasion of epidermis by ventrally migrating cells. 
6
 
Evidences suggest that development of congenital nevi may arise from response to epidermal 
cells secreted growth factors by precursors of Schwann cells reach epidermis during cutenous 
innervation.
7
 Studies demonstrating molecular difference between dermal and epidermal 
melanocytes support the double origin of skin melanocytes idea.
8
 
At the molecular level, intact BMP signalling partly contributes to early neural crest 
induction.
9
 Fate of trunk NCCs counts on Notch signalling activation acts on early progenitors 
cells preventing them taking neuranal fate instead of becoming neural crest cells.
10
 
Subsequent to induction, neural crest cells undergo epitheliel-mesencymal transition, lose 
their attachment to neighbouring cells and migrate. This mobility acquired by repression of E-
cadherin expresion via Snail/Slug transcription factors.
11
 WNT signalling is essential for its 
role in promoting cell fate towards melanoblast and mature melanocyte through B-catenin 
expression.
2, 12-14
  Further receptor tyrosine kinase c-KIT and its ligand; G protein coupled 
receptor EDNRB2 and its ligand endothelin-3; transcription factors Sox10, Pax3, MITF; are 
demonstrated to play crucial roles in melanocyte formation during embryogenesis.
5, 15-18
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1.3 Epidemiolgy of Cutaneous Malignant Melanoma 
1.3.1 Incidence of Cutaneous Malignant Melanoma  
Melanoma of the skin is the 5th common cancer in USA after prostate, breast, lung, 
colon and rectum cancers. Although 5% of skin cancer defined as melanoma, 75% of the 
deaths occur as a result of melanoma. American Cancer Society estimated 4.6% of the new 
cancer cases would be diagnosed as melanoma in 2013. Out of estimated 76,690 new 
melanomas,   approximately 45,060 cases would be diagnosed in men. Expected number of 
people died from malignant melanoma is 9,480 which are equal to 1.6 % of cancer death. 
Geographical variations, age, gender, anatomic location of the primary tumor may 
affect the incidence of melanoma. Latitude gradient for melanoma is taken into account as a 
feature of melanoma.
19, 20
 Fair skinned people living at low gratitudes in high incidence 
countries such as Australia, New Zealand, USA, Isaril, have highest rates of melanoma 
compared to high latitude counterparts and dark skinned residents of the countries.
21-23
 
Southern Europe populations (Italy, southern Spain and Balkans) are exceptions in the context 
of latitude graident. Assumed to be predominated by the overall darker pigmentary 
chracteristics, southern Europe populations demonstrates low incidence of melanoma. 
Compatible with these findings World Health Organisation estimated incidence of melanoma 
to be high in Scandinavian countries in Europe (Fig 1.2). 
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                                  Age Standardised Rate (European) per 100,000 
          Figure1.2 Estimated Incidence of Malignant Melanoma of skin in both sexes, 2012 
Source: Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber 
H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 
countries in 2012. Eur J Cancer. 2013 Apr; 49(6):1374-403. 
Starting from 40 years of age, age-dependent incidence of melanoma gradually rises 
and peaks at the seventh and eight decades. 
24-28
 People around 50-60 years of age have high 
incidence of primary tumor on the trunk compared to those around 80s whose primary tumor 
locate in the head and neck.
27-31
 Males are more prone to melanoma in low latitude countries. 
Thus,  melanoma incidence have been higher among men in Australia and USA or have been 
increased in New Zealand compared to females.
32
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1.3.2  Risk Factors of Cutaneous Malignant Melanoma 
Genetic predisposition and exposure to environmental agents promote incidence of 
melanoma. Elevated numbers of atypical moles inherited in a familial setting defined as 
dysplastic nevus syndrome and may delevop melanoma with a higher penetrance rate and 
earlier onset than sporadic melanoma.
33-35
 
A Germline mutation in the cyclin dependent kinase inhibitor 2 gene (CDKN2A, 
chromosome 9p21) is a major indicator of susceptibility to melanoma progression in familial 
type of melanoma.
36, 37
 20-40% of the familial melanoma is originated from germline 
alterations in CDKN2A gene.
38, 39
 Coinheretance of a low –risk susceptibility gene, 
melanocortin-1 receptor (MC1R) in red haired vairants with CDKN2A mutations has found to 
increase the risk of melanoma from 50% to 80%.
40, 41
 With less frequency, abberations in 
CDK4 or CDK6 can be detected in melanoma. Mutations in CDK4 binding site of p16 
INK4A (Arg24CyS Arg24 His mutation) resulting in impaired binding of p16INK4A to 
CDK4 may seen in melanoma prone families. 
42-45
 
The only environmental factor sunlight may increase the risk of melanoma through its 
UV components. UV exposure is indicated to be a risk factor for melanoma in several studies 
such as, (1) increased incidence up to 10 to 20 fold in fair skinned people located in close 
proximity to equator
46
; (2) XP diagnosed people have 1,000 fold increase incidence to 
melanoma compared to average population
47
; (3) UV radiation induced other types of skin 
cancer history elevates the risks up to 3 fold compared to patients without history
48, 49
  and (4) 
tendency to burn and freckles are phenotypic measures raise risk nearly two fold in all 
populations.
50
 Exposure pattern of sunlight is also important in melanoma. Common view 
supports higher risks of melanoma caused by intermittent sun exposure compared to chronic 
or cumulative sun exposure.
51-53
 Differences in sun exposure patterns on specific locations 
with abberant genetic backgrounds also have influence on types of melanoma. 
54
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1.4 Cutaneous Malignant Melanoma Genetics   
A better understanding of molecular changes in melanoma pathogenesis is beneficial for 
a better classification of patients and thus improving treatment options. So far, molecular 
researchs in melanoma have provided insights about abberations in cell cycle regulatory and 
cell signalling processes contributing melanomagenesis. Vast majority of malignant 
melanoma cases resulting from either presence of germline or somatic mutations in these 
pathways. Cross-talk between these pathways either is helpfull to partially control the 
resulting impairment or worsen the pathogenesis depending on the number of effected 
processes. 
 
1.4.1  Abberant Cell Cycle Regulation of CMM 
Phosphorylation status of pRB in the G1/S phase is a crucial step for cell cycle 
regulation thus, pRB serves as gatekeeper protein. .Entrance to S phase from G1 phase 
requires phosphorylation of pRB by cyclin-Cdk complexes, resulting in releasing E2F 
transcription factor from pRB, leading to expression of essential genes for G1/S transition. 
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                           Figure 1.3 The CDKN2A locus and cell cycle control 
 Source: Aleksandar Sekulic, MD, PhD, Paul Haluska Jr, MD, PhD, Arlo J. Miller, MD, PhD, 
Josep Genebriera De Lamo, MD, Samuel Ejadi, MD, Jose S. Pulido, MD, MS, MPH, MBA, 
Diva R. Salomao, MD, Erik C. Thorland, PhD, Richard G. Vile, PhD, David L. Swanson, 
MD, Barbara A. Pockaj, MD, Susan D. Laman, MD, MPH, Mark R. Pittelkow, MD, and 
Svetomir N. Markovic, MD, PhD. Malignant Melanoma in the 21st Century: The Emerging 
Molecular Landscape. Mayo Clin Proc. 2008.            
CDKN2A gene encodes 2 structurally particular proteins, p16 INK4a and p14 ARF, 
functioning in the cell cycle regulation as tumor supressors.
55
 Hypophosparylation status of 
pRB is maintained directly by p16 INK4a or indirectly by p14 ARF. In presence of cdk 
8 
 
inhibitor kinase (CKI); p16 INK4a inhibits cyclinD1-cdk4/6 complex activity, enabling pRB 
to sequester E2F and subsequently, lead to cell cycle arrest. Alternative splice variant of 
CDKN2A, p14 ARF protein indirectly controls pRB status in a same manner of p16 INK4a, 
via stabilizing levels of p53 protein, inhibiting its interaction with MDM2. In normal cellular 
conditions, p53 is target of MDM2 protein leading its ubiqutination and subsequent 
degradation in proteosomes.
56
 DNA damage triggers p53 accumulation in the cell via 
sequestering of MDM2 by p14 ARF.
57
 Activation of p53 induces another CKI protein p21,  
which, prevents phosphorylation of pRB via cyclin E/Cdk2 complex.(Fig1.3) In contrast to 
other malignancies, p53 mutation is very low
58
 in melanoma confirming reliance to p14 ARF 
control.  
Melanoma associated CDKN2A mutations either resulted in low expression of p16 
INK4A
59, 60
 or p14 ARF alone
61, 62
 or both 
63-67
 indicates that each tumor supressor fulfill its 
own particular role against development of melanoma. 
  
1.4.2  Abberant Cell Signalling in CMM  
Receptor tyrosine kinases (RTKs) initiated proliferation via mitogen activated protein 
kinase (MAPK) pathway and survival via phosphoinosite 3kinase/ AKT (PI3K/AKT) 
pathway are in the centre of sporadic melanoma pathogenesis. 
1.4.2.1   MAPK pathway 
Activation upon RTKs ligand to RTKs or integrin adhesion to extracellular matrix; 
GDP binding to RAS protein (NRAS/KRAS/HRAS) is replaced with GTP, transfering RAS 
to its active state.
68, 69
 RAS activation triggers its downstream effectors; RAF/MEK/ERK 
serine threonine kinases. Any changes resulting in hyperphosphorylation of ERK through 
MAPK cascade contributes to cellular proliferation and survival of melanoma patients in the 
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90% of the cases.
70
  50-70% mutation is detected in RAF gene, and with a 90% frequency in 
BRAF resulting from substitution of valine with glutamic acid at 600 position. 
71-74
 RAF 
mutation increases the kinase activity to 10-480 fold compared to wild type.
75
 Transcription 
factors; MITF 
76
(microphthalmia-associated transcription factor)and BRN-2 
77
(POU domain 
class 3 transcription factor), the cell cycle regulators cyclin D1 and p16 CDKN2A 
78, 79
; and 
the tumor maintenance enzymes, matrix metalloproteinase-1 (MMP-1) 
80
 and inducible nitric 
oxide synthase (iNOS)
81
  act as downstream effectors of BRAF mutation in melanoma. 
Neoangiogenesis is also maintained by BRAFV600E mutation via inducing VEGF 
secretion.
82
 BRAF mutation is found to be present in 70-80 % common benign nevi 
suggesting that BRAF mutation is a very early event in melanomagenesis and by its own is 
not sufficient to drive melanoma development. 
83-85
  
Independent of PI3K-AKT induced mTOR activation, MAPK induced ERK1/2 and 
ribosomal S6 kinase (RSK1) also act on TSC1/TSC2 complex in a same manner of AKT. 
MNK1 and MNK2, downstream kinases of ERK, also directly phosporylate eukaryotic 
translation initiation factor 4E (eIF4E). Upon mTORC 1 activation, eIF4E is released from its 
binding protein; leading to subsequent formation of eIF4E multisubunit complex, inducing 
cap-dependent protein translation, and increased translation of mRNAs with regulatory 
elements in the 5'-untranslated terminal regions (5'-UTR) of its downstream target genes (e.g., 
c-myc, ornithine decarboxylase and cyclin D1), which are required for G1-to-S phase 
transition.
86, 87
 
 cAMP has demonstrated to have an influence on MAPK pathway.
88, 89
 The mechanism 
how cAMP regulates MAPK pathway was brought up by Scott et al. A kinase anchoring 
protein 13 (AKAP13) plays a crucial role in this regulation by translocating cAMP induced 
PKA to near vicinity of RAF-MEK-ERK scaffold protein KSR1 and sustaining tha MAPK 
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stimulation by phosphorylation of KSR1. Moreoever, AKAP13 constitutes a core complex 
with KSR1 and functions as enhancer of the process as it keeps RAF close to MEK. 
90
    
1.4.2.2  PI3K-AKT Pathway 
Loss of intrinsic GTPase activity of NRAS due to substitution of glutamine to arginine 
at 61 position (Q61R) is seen 90% of overall 30% mutations among RAS family.
91, 92
  BRAF 
and NRAS mutations rarely coexist, regarding implications in the same cascade.
72, 93
 
However, NRAS mutations can activate both MAPK and PI3K signalling simultaneously. 
Oncogenic NRAS activates PI3K to phosphorylate  the second mesenger 
phosphotadylinositol 4,5 biphosphate(PIP2) to PIP3.
94
 Protein kinase B (AKT) activation is 
maintained by PIP3 via phosphoinositide-dependent kinase-1(PDK1).
95-97
 AKT is a 
serine/threonine kinase which is involved in cell cycle progression, survival, metabolism and 
migration via phosphorylation of many physiological substrates upon activation. 
98-102
 Among 
3 isoforms of AKT (AKT1, AKT2, AKT3), AKT3 is preferentially activated in sporadic 
melanomas up to 60% of the cases.
103, 104
 This additional activation of AKT3 is separate from 
loss of functional phosphatase and tensin homolog (PTEN) which acts as a lipid phosphatase 
that regulates intracellular PIP3 levels.
75
 Thus, homozygous mutations or deletions in tumor 
supressor PTEN contribute abberant activation of AKT. 
11 
 
 
 
Figure 1.4 schematic representations of key therapeutic targets in the PI3K/Akt and MAPK 
pathways 
Source: Adapted from SubbaRao V. Madhunapantula, Paul J. Mosca8 and Gavin P. 
Robertson. The Akt signaling pathway. Cancer Biology & Therapy, 2011. 
Phosphorylation of proapoptotic proteins; BAD
105, 106
, caspase-9
107
 ,MDM2 
108-110
, 
forkhead transcription factors
111, 112
 leading to inactivation of these proteins whereas NF-kB 
activation
104, 113, 114
 is the result of phosphorylation in AKT driven prevention of apoptosis. 
Down regulation of Cdk inhibitor proteins p21 cif1/WAF1, p27 kip1 and stabilization of 
CylinD1 and Cyclin E at G1/S transition and inhibition of Wee1 at G2/M transition is 
controlled under phosphorylation of AKT in the process of cellular proliferation. 
115-117
 AKT 
is also shown to interact with GSK3Beta, which is a part of multiprotein complex regulating 
B-catenin degradation in the cytosol in the absence of WNT signalling, leading its 
ubiqutination and nuclear translocation of B catenin.
118
 (Fig 1.4) 
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Major downstream effector of AKT is mammalian target of rapamycin (mTOR) which 
is a serine/threonine kinase. mTOR has two distinct multiprotein complexes mTORC1 and 
mTORC2. mTORC1 gathers information from various extra and intra cellular signals like 
growth factor induced PI3K –AKT pathway, controlling processes such as protein and lipid 
synthesis and autophagy. AKT can activate mTOR via phosphorylation directly by acting on 
the negative regulator PRAS40 of mTORC1 complex, or indirectly by inhibiting GAP activity 
of TSC1/TSC2 heterodimer on Rheb which stimulates mTORC1. mTORC2 comlex of mTOR 
is a positive coregulator of AKT by phosphorylating it on hydrophobic motif Ser437 for its 
maximal activation. However, defeciency in ser437 phosphorylation of AKT by mTORC2 is 
only related with phosphorylation capability of AKT to its some targets such as FOXO but not 
all.
119
 
1.4.2.3  Regulation of MITF            
Microphthalmia associated transcription factor (MITF) regulates melanocytic 
development, differentiation and maintenance.
120, 121
 Pigmentation enzyme genes, as TYR, 
TYRP1, and DCT; melanoma marker genes including SILV/gp100/, HMB45, 
MLANA/MART1, and AIM1 and prognostically relevant melanoma marker TRPM1 is 
regulated by MITF dependent fashion.
122-130
 MITF expression control needs fine tunning 
since high and low levels of MITF results in cycle arrest and differentiation via p16 CDKN2A 
and p21cip1 WAF1 induction or apoptosis, respectively.
131, 132
  However, melanoma cells are 
thought to maintain an intermediate level of MITF expression to promote cell proliferation 
along with tumorigenesis. MITF activation relies on cross talk between MAPK and 
melanocortin pathway (MC1R).(Fig 1.5) MC1R activation is needed for MITF expression 
whereas MAPK is needed for MITF activation.
55
 BRAF mutation in MAPK is shown to 
control MITF protein by increasing MITF expression through BRN2 transcription factor 
counterbalance to MAPK dependent degradation of MITF.
133, 134
 Further downstream effector 
13 
 
of WNT signaling, B-catenin is shown to regulate MITF expression in TCF/LEF/DNA 
consensus dependent transactivation of MITF promoter.
135
 
                 
                                               Figure 1.5 MITF signaling 
Source: Aleksandar Sekulic, MD,PhD, Paul Haluska Jr, MD, PhD, Arlo J. Miller, MD, PhD, 
Josep Genebriera De Lamo, MD, Samuel Ejadi, MD, Jose S. Pulido, MD, MS, MPH, MBA6, 
Diva R. Salomao, MD, Erik C. Thorland, PhD, Richard G. Vile, PhD, David L. Swanson, 
MD, Barbara A. Pockaj, MD, Susan D. Laman, MD, MPH, Mark R. Pittelkow, MD, and 
Svetomir N. Markovic, MD, PhD. Malignant Melanoma in the 21st Century: The Emerging 
Molecular Landscape. Mayo Clin Proc. 2008.            
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1.4.2.4 Deficiency in KIT and MC1R Receptors 
Abberant activation or deactivation of receptors contributes to melanoma progression 
independent of downstream mutations. So far changes in KIT and MC1R genes have been 
detected in melanoma. KIT also known as c-KIT encodes a receptor tyrosine kinase, 
belonging to PDGF family.  Although it is essential for melanocyte survival, its expression is 
lost in nevi. Mutation or gene amplification dependent overexpression of KIT triggers 
downstream proliferative and  pro survival pathways. Mutations occurred in K642E, L576P, 
D816H, and V559A positions may either provoke KIT dimerization in the absence of stem 
cell factor or hinder an auto control conformational change to its unstimulated status. 
136-138
 It 
is also noted that abberant expression of KIT is found in some cases that do not harbor any 
gene amplifications or mutation.  
Polymorphisms seen in MC1R which is a G-protein coupled receptor increase the UV 
induced susceptibility to melanoma. Upon UV exposure; keratinocytes, increase transcription 
and secretion of alfa MSH, activating intracellular melanocortin pathway to overcome UV 
effects by producing melanin resulting in tanning.
139-141
 Germline polymorphisms in MC1R 
receptor lessen expression of MITF and prevents tanning in light skinned and red headed 
people, making them vulnerable to melanoma.
142
  
143, 144
      
1.4.2.5 Notch Signalling 
Expression levels of Notch receptors and ligands are found to be elevated in atypical 
nevi and melanoma compared to common mole. 
145, 146
 Notch1 interacts with (1)Beta-catenin , 
which  acts as a downstream effector of WNT signaling and interacts  with N-cadherin
147
; (2) 
MAPK and PI3K/AKT with an unknown way and stimulate transition to vertical growth 
phase
148
; (3) NF-kB and provides prolonged residence in nucleus of T cells.
149
 Further, notch1 
signaling is essential for RAS mediated transformation where impairments in notch1 
signalling cause significant reduction RAS mediated signaling.
150, 151
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1.5 Current Evaluation of Cutaneous Malignant Melanoma  
A patient can be diagnosed with melanoma depending on clinical and histopathological 
assesments. Clinical diagnostic approaches differ from histopathological ones in the devices 
they use. Especially radiological devices are used in clinical assessment of node involvements 
where as light microscopy is used in the latter one. Besides, with a slight difference in details, 
both methods come up with same result considering stages. Presence or absence of node 
involvement or distant metastasis is sufficient for clinical staging. However a deeper 
understanding of primary tumor, number of nodes, locations of distant metastasis is given by 
histopathological staging. 
1.5.1  Clinical Evaluation  
An experienced dermatologist can diagnose the lesion of interest according to the 
clinical ABCDs criterias of the melanoma.
152
 ABCD refers to assymetry, border irregularity, 
color distribution, and diameter of the lession that can be detected by naked eye.(Table 1.1) 
Since asymmetrical changes in size, shape or color, accompanied with itching and bleeding 
may develop in time, “E” of evoltion is added to ABCD rule. 153  Atypical nevus can be 
identified more easily beacuse of the differences seen in patterns compared to benign nevus of 
the same patient examined prior to selected nevi. This is called ugly duckling sign.
154
 For 
questionable lessions non-invasive dermascopy method can be applied to distinguish between 
atypical nevus and melanoma.
54
 Methods give insight about architecture of the tumor.
155
 
Algorithmic methods such as the ABCD rule of dermoscopy
156
, the 7-point checklist of 
dermoscopy 
157
, or Menzies’ scroring method158 are valid and reliable during dermascopy. 
Dermascopy may increase detection of cutaneous melanoma with a sensitivity of up to 
92%and a specificity of up to 99% depending on the individual experience of the clinician.
159
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                     Table 1.1 Clinical diagnostic rules for melanoma, the ABCD criteria.                  
Source: Franziska Brehmer, M.D., Martina Ulrich, M.D., Holger A. Haenssle, M.D. Strategies 
for early recognition of cutaneous melanoma—present and future. Dermatol Pract Concept 
2012.  
1.5.2  Histopathological Evaluation 
Histopathological evaluation can be used for both diagnostic and prognostic purposes. 
When a suspicious lesion is removed by either excisional or incisional surgery; tumor 
thickness (Breslow’s Depth), ulceration of the tumor, and mitotic rate are the first three 
parameters to define the primary tumor (T). 
54
 
Tumor thickness so called Breslow’s depth is the major definer of the T category. It’s 
the vertical measurement of the specimen in millimeters from the top of the granular layer of 
epidermis to the deepest point of invasion.
160
 Though thickness negatively corellates with 
survival, thinner melanomas have shown to metastasize with a rate of 4.8%.
161, 162
 Therefore, 
Clark’s level, ulceration, mitotic rate and regression rate should be taken into account for 
further assessment of thin melanomas.
161
  
Second determinant and contributor of T staging is ulceration. Ulceration is defined as 
the absence of stratum corneum and basal membrane accompanied with host response and 
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thinning, effacement or reactive hyperplasia of the surrounding epidermis without any known 
prior surgery.
163
 Ulceration can be refered as a sign of metastatis, since the survival rates of 
any T stage with ulceration is equal to following T stage without ulceration.
164
  
Clark’s level of invasion for the discremination of T1a and T1b is replaced with 
mitotic rate in the 7th edition of AJCC melanoma staging. 
54Clark’s level of invasion is based 
on relating anatomic landmarks to tumor depth for melanomas ≤1mm thin.165  Compared to 
Breslow depth which is a continous variable, a discrete variable such as Clark’s level has 
shown weaker correlation with patient survival.
163, 166
  In addition, discremination differences 
in Clark’s levels originating from variation in pathologists, lead to classification errors.  
Prognostic significance of mitotic rate and ulceration in concert with Breslow depth ruled out 
the importance of Clark’s level only if these two parameters can be assessed. 165 Mitotic rate 
corresponds to the number of mitotis in the hotspots in dermis within a range of 1mm².
167
 The 
significant threshold relevant to survival is 1mitosis/mm² for classification of T1a and T1b 
melanomas.
161, 163
 
Regional lymph node involvement in the prognosis of melanoma is a major prognostic 
factor that strongly correlates with 10 year survival rates of the patients.
167
 Node involvement 
can be classified in three groups; micrometastatsis, macrometastasis and intralymphatic 
metastasis. Lymph nodes metastasis which can not be diagnosed clinically by palpation or 
imagining techniques but can be assesed histopathologically following sentinel lymph node 
biopsy (SLNB) or elective lymphadenectomy is defined as micrometastasis.
168
 
Macrometastasis is the case where node involvelment is identified clinically, then confirmed 
histopathologically. Intralympatic metastasis can be either in form of in- transit or satellite 
lessions related with poor prognosis. Both are discontinous lessions apart from the primary 
tumor with a differential in length of location. Discontinous lesions within the 5cm or more 
than 5 cm of primary tumor are called satellite and in-transit metastasis, respectively.
169
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Microsatellites are nests of tumor cells with a ≥0.05 diameter disconnected from the primary 
tumor by only dermis, categorized with in the same group as satellite or in-transit metastasis. 
Distant metastasis is categorized by the site of metastasis and lactate dehydrogenase 
(LDH) levels. The survival rates of patients with nonvisceral, lung or visceral metastasis 
differ greatly, with a poor prognosis in the direction of visceral metastasis.
167
 Serum LDH 
level is an independent prognostic indicator of survival in stage IV melanoma patients. 
167, 170-
172
Therefore confirmation of high level LDH without any detection of distant metastasis in 
any site still defined as distant metastasis.
167
 
Any type of metastasis detected without any primary site is considered to be 
equivalent of metastasis with known primary sites when staging. The circumstances are 
described as spontenous regression of the primary site before detection. 
173
 A similar or in 
some cases better survival of metastatic melanoma patients without known primary sites 
compared to patients with known primary sites supports the idea of effective immune 
response in those patients contributing primary site regression and better prognosis.
174, 175
 
The criterias mentioned so far are placed in the current tumor classification system of 
melanoma described in the 7th edition of AJCC (Table 1.2). 
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                   Table 1.2 TNM staging categories for Cutaneous Malignant Melanoma 
Source: Zendee Elaba, Michael J. Murphy, Philip Kerr, and Jane M. Grant-Kels. Staging of 
Melanoma. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma, 
2012. 
1.6  Melanoma Biomarkers 
Parameters used to assign patients in to subgroups are either morphological or 
histopathological. This approach is a crude way of subgrouping patients since the genetic 
dynamics of patients are variable. Thus, conventional treatments do not accomplish the 
proposed outcome. For this reason, markers such as tissue-based, serological and molecular 
are under investigation for a better diagnostic and prognostic classification. 
Imminohistochemistry, gene expression profiling, gene mutation analysis and comparative 
genomic hybridization techniques are used in this purpose. 
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Immunohistochemical staining (IHC) of a panel including melanoma lineage markers 
such as s100, MART-1, gp100/HMB45 are qualified to be diagnostic discriminators between 
melanoma and non-melanoma cells. IHC staining of Ki67 with MIB-1 antibody is widely 
used to distinguish benign from malignant melanoma.
176
 AJCC also finds this approach alone 
acceptable in the cases of evident morphological malignant cells features in the IHC staining 
of nodes to approve nodal metastasis.
176
 
  So far there are three serological markers identified as prognostic markers of 
metastasis; S100-beta, melanoma inhibitory activity (MIA) and LDH. Crediting S100-beta as 
inferior to MIA, S100-beta and MIA are used as prognostic indicators of relapse and 
metastasis in the follow up of the patients.
172, 177
 Besides in the absence of metastasis or in 
tumor free situation, both have no significance to give insight into earlier stages.
178
 Moreover 
in the case of detection of micrometastasis, S100-beta also fails to identify the 
micrometastasis where SLNB still remains as identification approach.
179
 Among these 3 
serological markers, lactate dehydrogenase (LDH) has shown to be the strongest independent 
prognostic factor that its elevated amounts in the serum is accepted to be the indicator of 
distant metastasis regardless of approved presence and  accrued into AJCC classification 
system as stage M1c.
180
 
Discovery of BRAF mutations in the MAPK pathway with a incidence rate of 70% in 
melanoma patients led to personalized treatment with BRAF inhibitors. Especially, testing 
BRAFV600E mutation which accounts for 90% of the BRAF mutations is an eligibility 
criterion for patients with metastatic or unresectable melanoma to be treated with BRAF and 
MEK inhibitors. 
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1.7  Autologous Vaccination and Melanoma, Impact of Autologous Vaccination on 
Survival of Cutaneous Malignant Melanoma Patients 
1.7.1 Autologous Vaccination  
Discovery of tumor antigen presentation is recognized by T cells on solid tumors,   
yields invesigators to develop immunotherapeutical approaches against cancer. Among them 
vaccination strategies are evaluated as an adjuvant treatment for melanoma. Aim of 
vaccination is to sensitize T cells against relevant tumor antigens.
181
Developing immune 
response through vaccination involves autologous or allogenic whole cell vaccines,  tumor 
specific peptide presentations or delivery of specific antigen presenting dendritic cells.
182
 
The rationale behind the whole cell vaccination is to introduce adaptive immune 
response companents with high amount of tumor antigens on actual tumor cells delivered by 
injection. Therefore, whole cell vaccination is known to be polyvalent, eliciting immune 
response against multiple antigens.
183
 Depending on source, whole cell vaccination is 
categorized as (1) autologous, originated from and delivered to same patient or (2) allogenic, 
originated from various patients and delivered to a different recipient. Autologous whole cell 
vaccination has its own advantages over the latter one, such as having unique patient specific 
antigens and appropriate HLA match for ideal antigen presentation. However, obstacles 
remain in the procedure against effective application. Patients need to have available tumors 
for resection to obtain tumor cells. Nonetheless amount of cells occupied from any of them, 
aren’t sufficient to produce more than two or three doses. Meanwhile the duration of 
harvesting the tumor and production of vaccine may give rise to unexpected tumor 
progression that would rule out the effect of vaccine. On the other hand, allogenic whole cell 
vaccines have shared antigens relevant to specific tumor from various patients in all stages. 
Moreoever, availability of abundant source provides administration of vaccines for a 
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prolonged time. The only drawback of this approach is lack of important antigens to provoke 
immune response in specific patients.
184
 
  An established autologous whole cell vaccine for melanoma relies on studies done in 
murines with metastatic mammary carcinoma.
185
 Adaptation and optimization of this 
approach into clinic trial applications of melanoma is perfomed by Berd et al. Basically, 
previously harvested melanoma tumor cells are first irradiated and conjugated to DNPs mixed 
then mixed with BCG prior to administration are delivered via intradermal injection on the 
day of treatment. 
186
  Administration of the vaccine is as cruical as preparation for its utmost 
effect in patients. 
187
 Procedure starts with DNP and cyclophosphamide injection prior to 
vaccination. Cyclophosphamide is used for its immunopotentiating properties  
188-190
 
Vaccination continues in intervals up to 8 doses. 
191
 
1.7.2  Role of Autologous Vaccination on Cutaneous Malignant Melanoma Patient’s 
Survival 
The settled preparation and administration of melanoma vaccination called MVAX 
was subjected to clinical trials to assess its effect on patient’s survival. Phase I trial was 
evaluated on 83 stage IV metastic melanoma patients. In total 11 of the patients responded 
including; 2 complete, 4 partial and 5 mixed. Subjects of complete responses and 2 of partial 
response had lung metastasis.  Response duration of complete responses were 12, 29 months 
whereas partial response last for 5, 6, 8 and 47+ months in patients. 
192
 As a post-surgical 
adjuvant application, 214 stage III patients treated with MVAX. 5 year overall survival was 
increased to 44% when compared to 20-25% resulted from surgical alone. 
193
 Phase III trials 
were conducted to evaluate effeciency of MVAX over HDI in stage IIIB –IIIC melanoma 
patients as post surgical adjuvant therapy. At the edge of marketing approval, MVAX was 
found to be inadequate to pass sterility testing since fresh vaccine shelf life of MVAX was too 
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short. A great deal of vaccine amount were found to be contaminated with aneorobic 
Propionibacterium acnes.
187
 
Following FDA termination of fresh MVAX trial, a frozen version of MVAX was 
developed, having shelf life of months instead of hours. FDA acknowledged it as a new 
vaccine which should be subjected to trials from the beginning due to dead tumor cell content 
of the vaccine. Frozen MVAX was demonstrated to be equally effective and more importantly 
safe in comparison to fresh MVAX in phase I –II trials.187Contraversial results from a 
previous study
194
 and insufficient funding were the end of planned phase III trial for frozen 
MVAX. 
187
 
1.8 A Crosstalk between CT Gene Expression and Tregs in Melanoma 
Expressions of CT genes are normally restricted to immune privileged germ cells of 
testis and placenta but abnormal expression patterns are also found in various cancer types. 
195
Their importance for immunotherapy resides in the fact that any therapy developed against 
them will directly affect the tumor cells in the relevant cancer, considering their tumor 
specific expression. Tumors expressing cancer testis antigens may demonstrate heterogeneous 
expression, increasing with elevated stages of cancer. Moreover, a CT gene expression in any 
type of cancer is found to be expressed in concert with multiple CT genes in that cancer. This 
escalating expression of co existing CT genes correlates with worse prognosis in increasing 
cancer stages of 1-3.
196
 
In a simplistic approach, considering these facts and high immunogenic potential of CT 
genes, one should expect to see elevated immune response in parallel with higher CT 
expression and elimination of cancer.  However, the microenvoriment established and 
maintained by tumors seem to have immunosuppressive properties, preventing recognition of 
presented CT epitopes on MHC class I and II molecules.   
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T regulatory cells of immune system have been demonstrated to take a part in 
diminishing antitumor T cell immunity.
197
Their normal role in immune system is to hinder 
autoimmune diseases  by repressing numbers and cytokine products of CD4CD25 T cells, 
CD8 T cells, already existing Th1 and Th2 cells. Therefore, presence of Tregs in tumor 
microenvironment suggested being one of the possible ways of immunosuppression.
198
 
Contribution of Tregs to melanoma progression has been evaluated. Study conducted by 
Mourmouras et al., underlines the importance of   Tregs presence   from   atypical nevi to 
vertical growth phase melanoma, proposing immunotolerance maintained by Tregs in the 
early melanomagenesis and support melanoma growth.
199
 Also, Tregs amounts are shown to 
be high in tumor infiltrated lymp nodes to peripheral blood in patients and peripheral blood of 
melanoma patients to healthy controls. 
200
Concordant with these results, Cebon et al. detected 
40% Treg population to all T cells infiltrating metastatic melanoma tumor tissues.They related 
presence of Tregs to immune suppression in their studies, concerning effects of NY-ESO-1 
ISCOMATRIX cancer vaccine in melanoma NY-ESO-1 positive melanoma patients after 
surgery with minimal residual disease (MRD) to metastic NY-ESO-1 positive patients. It’s 
been demonstrated that vaccine results in high immune response in   MRD patients to 
metastatic patients; in terms of providing strong DTH, circulating CD4 and CD8 T cells 
against NY-ESO-1 epitopes and prolonged disease free survival. 
197
 Higher abundance of 
Tregs in advanced disease compared to MRDs in concert with previous findings is a possible 
ground of tumor induced immune suppression in melanoma patients. Moreover, an additional 
contribution from melanoma cells expressing FoxP3, acting like Tregs and enhancing local 
immune suppressive environment has been demonstrated.
198
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1.9 An Overview of TGFα, CLDN1, CDX2, ERCC1 and LIG3 in Melanoma 
1.9.1 TGFα 
Abnormal expression of growth factors, receptors and their related signalling 
pathways are thought to have a role in transformation of melanocytes to melanomas. Among 
the mRNA levels of 11 growth factors that were compared between 19 human metastatic 
melanoma cell lines and  14 normal human foreskin melanocytes,  mRNA levels of TGFα was 
demonstrated to be characteristically  higher in melanoma cell lines as well as TGFβ2 and 
bFGF.
201
 TGFα has also been detected in the urine of primary and metastatic melanoma 
patients.
202, 203
 High structural homology in the receptor binding site with EGF, TGFα can 
stimulate autocrine mediated proliferation via binding and activating EGFR.
204
 However,  
EGFR activation is only detected in  BRAF V600E mutant melanomas treated with BRAF 
inhibitors.
205, 206
  
1.9.2 CLDN1 and CDX2 
Tight junctions are important for their role in maintaining cellular polarity,  and 
contribution to cellular transport, growth and differentiation.
207
 Among the tight junction 
proteins, claudins are most implicated and studied in the tumor formation and progression. 
208
 
Differential expression patterns of claudins are tissue specific and may end up in both tumor 
suppression and promotion. 
209
  In the case of CLDN1 expression in melanoma patients, it has 
been demonstrated that in the presence of high PKC, CLDN1 expression will increase and 
atypical localization of CLDN1 to nucleus or cytoplasm will occur. 
210
  By this way, not only 
the amount of CLDN1 in cell membrane lessens but also MMP-2 activation due to increased 
CLDN1 will be obtained. This will lead a decrease in tight junction integrity and an increase 
for higher capacity of motility and metastasis in melanoma patients. Further, the same group 
implicated the particular effect of PKA on trans locating CLDN1 to cytoplasm from nucleus 
which is a critical in the progression of melanoma. 
211
  The intermediate localization of 
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CLDN1 to nucleus has been proposed to be related with non-canonical WNT signaling which 
leads EMT transition in melanoma cells under PKC dependent manner. 
212
 On the contrary, 
Cohn et al. demonstrated that loss CLDN1 expression in metastatic melanoma when 
compared to benign or primary lesions. 
213
 
Though there are no published literature about CDX2 gene function in melanoma 
genesis, CDX2 is related to be transcriptional regulator of CLDN1 in colon cancer with 
CDX1 and GATA4 in concert with WNT signaling. Overexpression of these transcription 
factors impact on CLDN1 expression was also searched in renal epithelial and breast cancer 
and no change has been observed suggesting,   these transcription factors have control over up 
regulation of CLDN1 in colon specific manner.  
214 
1.9.3 ERCC1 and LIG3 
ERRC1 and LIG3 are genes both participating in DNA repair mechanisms.  ERCC1/ 
XPF heterodimer endonuclease is functional in nucleotide exchange repair (NER) and has 
roles in interstrand crosslinks repair (ICL) and double strand break repair (DSB)
215
. Platinum 
drugs used as chemotherapeutics in cancer treatment such as cisplatin cause inter and intra 
strand crosslinkings.ERCC1/XPF are important for repairing cisplatin caused DNA damage, 
making them critical for resistance. It has been demonstrated that melanoma cell lines may 
have intrinsic and acquired resistance to cisplatin. The former may result from high 
expression pattern of ERCC1 and XPF in melanoma cells occurred spontaneously. The latter 
may arise from cisplatin induced increase of these two genes via MAPK pathway with minor 
contribution of low expreesion DUSP6, resulting in continuum ERK activation and high 
ERCC1 expression in particular.
216
  
LIG3, which is vertebrate restricted, along with XRRC1 have roles in short patch base 
excision repair  (BER),  single strand break repair, NER in dividing cells and DNA ligase IV 
dependent non homologous end joining pathway as back up. 
217
 No direct linking of 
27 
 
expression of LG3 to any cancer type has been proposed including melanoma. Though 
contribution of LIG3 SNPs to increased risk for cancer types such as breast
218
,  pancreatic
219
,  
young on set lung
220
,  colorectal
221
, non-small cell lung cancer
222
 have been searched. Only 
cancer which one LIG3 SNP is linked significantly with altered risk of cancer was found to be 
pancreatic cancer 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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2 OBJECTIVES AND RATIONALES 
Due to lack of diagnostic markers, curable malignant melanoma in the early stages 
escapes from detection and thus results in uncontrollable disease. Although surgery is the only 
treatment of stage I melanoma upon early detection, there are various post surgical treatment 
options in the following stages. Yet, still choosing the appropriate post surgical adjuvant 
therapy for a patient is an issue, considering absence of informative prognostic biomarkers. 
Melanoma, being highly immunogenic, has been a target for immunologists and 
oncologist to elaminate cancer. Autologous vaccination of malignant melanoma patients 
subsequent to surgery has been one of the approaches trialed so far. Still, to determine the 
patients who will gain favour from this treatment is critical. 
Therefore we aimed to identify prognostic marker/s to define a subpopulation of 
malignant melanoma patients who could be candidates for autologous vaccination post 
surgically. 
In this study, we started with a short list of potential prognostic biomarkers identified 
using USAT analysis, a unique bioinformatics tool developed in our laboratory. USAT is 
composed of statistical packages (cox propotional hazards regression model, maximally 
selected rank statistics, log-rank test) found in R which seeks correlation of gene expression 
profiles and survival. In addition to EMT markers, DNA repair genes, EGFR ligand and 
AKAP gene in our list; cancer testis genes, SSX1 and MAGEA1 are the ones that gain our 
full attention. CT genes are known to be highly immunogenic; however, increased 
expressions of them are related with poor prognosis in melanoma. 
223, 224
 So, we hypothesized 
that autologous vaccination may favour patients with expressing high CT genes by sensitizing 
their immune systems with these antigens and overcome the immunesuppression. With the 
other selected prospective biomarker genes, I tried to demonstrate a possible impact of 
29 
 
autologous vaccination in a specific subset of malignant melanoma patients expressing those 
genes.  
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3 MATERIALS AND METHODS 
3.1 MATERIALS 
3.1.1 General Laboratory Regeants 
A variaty of regaeants and kits branded from SIGMA-ALDRICH (St.Louis, MO, 
USA), Ambion (Carlsbad, CA, U.S.), Invitrogen (Carlsbad, CA, USA) ,Cayman Chemical 
(Ann Arbor, MI, USA), Applied Biosystems  (Carlsbad, CA, U.S.) used in this thesis to 
accomplish the project. Chemical Reagents such as Ethanol, Choloroform, Isopropanol were 
acquired from SIGMA-ALDRICH (St.Louis, MO, USA). RNAse Zap, Nuclease Free Water 
(not DEPC-Treated) were aquired from Ambion (Carlsbad, CA, U.S.). DMSO (Dimethyl 
sulfoxide) was acquired from AppliChem (Darmstadt, Germany). Tri-Reagent was aquired 
from Ambion (Carlsbad, CA, USA).Qubit™ RNA BR Assay Kit and DNA-free™ Kit were 
acquired from Invitrogen (Carlsbad, CA, USA). Agilent RNA 6000 Nano Kit was acquired 
from Agilent Technologies (Santa Clara, CA, USA). RevertAid First Strand cDNA Synthesis 
Kit was acquired from Thermo Scientific (Waltham, MA, USA). OneTaq Quick-Load 2X 
Master Mix with Standard Buffer was acquired from New England Biolabs (Ipswich, MA, 
USA). Taqman Gene Expression Assays and TaqMan Universal PCR Master Mix were 
acquired from Applied Biosystems (Carlsbad, CA, U.S.) Gefitinib was acquired from Cayman 
Chemnicals (Ann Arbor, MI, USA). 
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3.1.2  Cell Culture Materials and Reagents 
Materials used in Cell Culture procedures; serological pipettes, cell culture scrapers 
and flasks were purchased from Costar Corning Incorporated (NY, USA), Sarstedt 
(Nümbrecht, Germany) and Greiner Bio One (Monroe, NC, USA), resprectively. SFCA 
(Surfactant-Free Cellulose Acetate) membrane Serum filter unit were purchased from Thermo 
Fisher – Nalgene (Waltham, MA, USA). Millex-FG Syringe Filter Unit was purchased from 
Merck MilliPore (Billerica, MA, USA). Rosswell Park Memorial Institute Medium (RPMI) 
was purchased from both Biochrom (Berlin, Germany) and Lonza (Basel, Switzerland).  Cell 
culture solutions; Trypsin-EDTA and Fetal Bovine Serum (FBS) were purchased from 
SIGMA-ALDRICH (St.Louis, MO, USA) and GIBCO (Carlsbad, CA, USA) as in order. L-
Glutamine and Pencilin –Streptomycin were purchased from HyClone (Rockford, USA). 
3.1.3  Gel Electrophoresis, Nanodrop, Qubit Fluorimeter, Agilent Bioanalyzer  
Gel Electrophoresis tank and power supply were bought from Hoefer Inc (Holliston, 
MA).  NanoDrop (ThermoScientific, Wilmington, USA) was used to asses the quantity and 
purity of the RNA samples.Further,   Qubit Fluorometer (Invitrogen, Carlsbad, CA, USA) was  
used to determine RNA quantity  in a more precise manner.  Bioanalyzer 2100 instrument 
(Agilent Technologies, Santa Clara, CA, USA) was used to qualify the RNA integrity of the 
samples. 
3.1.4  Solutions and Media 
3.1.5  General Solutions 
Ethidium Bromide In order to obtain 100 ml Agarose Gel, 5 µl Ethidium Bromide is used 
from 10 mg/ ml stock solution with a final concentraion of 1X.   
50X Tris-Acetate-EDTA (TAE) 242 gr of Tris base; 37.2 g of Tritiplex III (EDTA);  57.1 ml 
of glacial acetic acid,  with 1 L ddH2O left to dissolve overnight and autoclaved. 
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3.1.5.1  Cell Culture Solutions and Media 
RPMI Complete Medium 10% or %20 FBS, 1% L-Glutamine and 1% Penicilin-
Streptomycin of the total media amount were filtered with 0.2µm syringe filter and added to 
the media. Complete Media stored at 4 ºC. 
Freezing Medium Freezing medium was obtained from FBS and DMSO with 9:1 ratio at the 
final amount. 
10X Phosphate Buffered Solution 80 gr of NaCl; 2 gr of KCl; 2.4 gr of KH2PO4, and 14.4 gr 
of Na2HPO4 were dissolved in 1 L of ddH2O.  10X PBS buffer was diluted to 1X PBS buffer 
by adding 450ml of ddH2O to 50 ml of 10X PBS. 1X solution was autoclaved and filtered 
with serum filter unit before use. 
0.25% Trypsin-EDTA (1X), Phenol Red Acquired from SIGMA-ALDRICH (St.Louis, MO, 
USA) 
L-Glutamine Acquired from HyClone (Rockford, USA). 
Fetal Bovine Serum (FBS) Acquired from GIBCO (Carlsbad, CA, USA) 
Penicilin-Streptomycin Acquired from HyClone (Rockford, USA). 
3.2 METHODS 
3.2.1 Cell Culture 
3.2.1.1  Origin of the Cell Lines Used in this Research 
36 melanoma cell lines derived from autologous vaccinated cutaneous malignant 
melanoma patients at Hadassah Hebrew University Hospital, Jerusalem, Israel (M1, M133, 
M154, M193, M202, M2025,  M217, M299, M307,  M336,  M51, M77,  M13, M139, M144, 
M145, M187, M189, M207, M21, M221, M24, M241, M332, M34, M346, M369, M371, 
M425, M433, M465, M517, M7, M84, SHM21.5, SHM20A2) and kindly provided by Dr. 
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Michael Lotem (Jerusalem, Israel). 8 Cell lines (M154, M202, M51, M13, M369, M371, 
SHM21.5, and M202) were lost due to contamination. 
3.2.1.2  Thawing the Cell Lines  
The Cryotubes of the cell lines filled with cell culture stocks of the relevant cells were 
taken from nitrogen tank. Each cell line was thawn by hand and immediately the content of 
the cryotubes transferred to the 15ml falcon tubes containing 5 ml medium at room 
temprature. Each tube was centrifuged at 1500 rpm for 3 min. The supernatant in each tube 
was aspirated and 2 ml fresh media was added to resuspend the cells. The cells were seeded 
on  25 mm culture flasks containing 4 ml media used during resuspension (alternatively, 
75mm culture flasks containing 10 ml media can be used based on the pellet amount). Then, 
each flask was placed in incubator. The cells with low amounts of pellets compared to others 
after centrifugation and a history with slow growth rate, were cultured with  media 
supplemented 20% FBS due to thawing. When the attachment and the recovery of the thawn 
cells were accomplished, media was changed directly to 10% FBS enriched media.  
3.2.1.3 Maintenance of the Cell Lines 
Each cell line was cultured in 1640 –RPMI media (BioChrom) enriched with either 
%10 or 20% Fetal Bovine Serum (Gibco), 1% L-Glutamine (HyClone), 1% penicillin and 
streptomcyn (HyClone).  All cell lines were incubated at 37 C°, with 5% CO2. They were 
supplemented with new media as often as they needed during daily regular controls. 
3.2.1.4 Passage of the Cell Lines 
Each cell line was seeded in to new flask when they reached the optimum confluency 
(70-80%). First, the media in each flask was aspirated.5 ml PBS was used to wash the cell 
lines in 75mm flask (1.5ml for 25 mm flask). Following removal of the PBS, 1.5 ml Trypsin-
EDTA was added to each flask and placed into incubator for 1-2min. The detached cell were 
resuspended with 5ml media and transferred in to 15ml falcon tubes. Each tube was 
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centrifuged at 1500 rpm for 3 minutes. The supernatant was removed and the pellet in each 
tube was resuspended with 2 ml media and seeded in to new flask containing 10ml media 
used in resuspension. 
3.2.1.5  Freezing the Cell Lines                    
The confluence cell lines were subjected to sucking of the media and washing with 
5ml PBS, and trypsinization with 2 ml Trypsin-EDTA respectively. After the removal of the 
supernatant containing media with trypsin-EDTA, the pellet of each cell line was resuspended 
in freezing media. The amount of freezing media was directly related to the confluency. Each 
cryotubes was filled with 1ml freezing media- cell suspension and immediately put into -20 
°C for 1-2 hours and transferred to -80°C for overnight incubation. Then the cryotubes were 
placed into nitrogen tank for long period storage. 
3.2.2  RNA Isolation 
Cell lines with an 80% confluency ratio treated with trypsin-EDTA and placed in 
incubator for 1-2min. Effect of tyrpsin neutralized with addition of fresh media to the flasks. 
Resuspension was taken into 15ml falcon tubes and cetrifuged at1500rpm for 3 min. The 
pellet of each cell line homogenized with 1 ml of  Tri-Reagent (Molecular Research Center) 
and centrifuged at 13000rpm for 15min at  4 C° subsequent to  incubation in room 
temprature(RT) for 5 min. Choloroform was added to each sample, incubated for 10min at RT 
and centrifuged (13000rpm, 15min, 4C°). RNA containing upper phases transferred into new 
1.5 ml eppendorfs. Centrifugations (13000rpm, 15min, 4C°) in between and after the addition 
of isopronal and alcohol, aided to precipitate and wash RNAs. In each step after 
centrifugation pellets were spotted and supernatans were carefully removed. Following 5 min 
air dry after alcohol washing, each sample dissolved in adequate amount of Nuclease Free 
Water (Ambion Carlsbad, CA, USA) depending on the pellet amount. First assesment of 
quantity and purity of the samples were performed by a Nanodrop spectrophotometer ND-
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1000 (NanoDrop Technologies; Wilmington, DE). Samples were stored at - 80 C° for further 
experiments. 
3.2.3  DNase Treatment 
A possible contamination of DNA during RNA isolation was elimanted by using 
DNA-Free kit (Ambion, Carlsbad, CA, USA). Kit consists of rDNAse I, 10X DNAse Buffer, 
10 X DNAse Inactivation reagents. 1µl rDNAse I for routine DNAse treatment (samples 
containing 200ng/ µl RNA or less) and 5µl DNAse Buffer with a final 1X concentration in 
50µl reaction were added to each sample with maximum amount of 10µg RNA. Process 
ensued with an incubation period for 30min at 37 C°. 5µl DNAse Inactivation reagent was 
added at a final 1X concentration to each sample and pippetted for 2 min. All samples were 
centrifuged at 10000 rpm for 2 min. Supernatants consisted of DNA free RNAs were 
transferred into new eppendorf tubes. 
3.2.4 Quality and Quantity assesment of the samples 
3.2.4.1  Qubit Quantification 
The quantity of RNA samples were measured with Qubit Fluorometer (Invitrogen) 
which is when compared to NanoDrop, more precise because of the direct binding of 
fluorescents to the nucleic acid of interest. Quant-it Reagent, buffer and standards were 
supplied with the Quant-it Kit (Invitrogen, Carlsbad, CA, USA). Working Solution was 
prepared by addition of 1 µl Quant-it reagent to 199 µl Quant-it buffers for each sample. First 
for the standards samples, 10 µl of each added to 190 µl working solution, incubated at RT for 
2 min and measured in order to calibrate the instrument. Later, 2µl of each sample mixed with 
198 µl working solution, incubated at RT for 2 min and measured with Qubit Flurometer. 
3.2.4.2  Agilent Bioanalyzer Qualification 
The integrity of RNA samples were determined by using Bioanalyzer 2100 instrument 
(Agilent Technologies, Santa Clara, CA, USA). Components of Agilent RNA 600 Nano Kit 
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are as follows; Agilent RNA 6000 Nano Chips, 2 Electrode Cleaners,  RNA 6000 
NanoLadder, RNA 6000 Nano Dye Concentrate, RNA 6000 Nano Marker, RNA 6000 Nano 
Gel Matrix. RNAse zap and nuclease free water (Ambion, Carlsbad, CA, U.S.) were loaded 
onto relevant chips and placed in the instrument in order to decontaminate and clean the 
electrodes of the instrument. First 550 µl of gel matrix was pippetted into a spin filter, 
centrifuged at 3500 rpm for 10 min at RT and aliquoted. 65 µl of filtered gel mixed with 1 µl 
gel dye and centrifuged at 10000 rpm for 10 min at RT. 9 µl of gel dye mix pipetted into 
corresponding wells on the chip. After pipetting the first well, it was diffused to the chip by 
the help of a pressure provided by a syringe. RNA marker and the ladder pipetted in to chip, 
first one to sample wells and ladder well and the second one only to the ladder well, 
resprectively. 1 µl of each sample loaded to each well on the chip and chip was replaced into 
the instrument. 2100 Expert Software (Agilent Technologies, Santa Clara, CA, USA) 
determined a RIN (RNA integrity number) with in a range 1 to 10, 10 meaning the intact 
RNA. All RNA preparations have a RIN (RNA integrity number) in a range between 8.5-10, 
with two exceptions (M34, RIN: 7.4; M77, RIN: 7.7) where base RIN is proposed to be 5.1 
for further qRT-PCR experiments.  
3.2.5 cDNA synthesis 
1350 ng of total RNA from each sample except M193, M217, M207, M425 with an 
amount of 900 ng and 240ng for M34 due to low concentrations, were used to synthesize first 
strand cDNA with RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, 
Waltham, MA, USA) in a total amount of 60 µl in separate 2 reactions which are 
simultaneously prepared. RNAs were incubated with appropriate amount of random hexamer 
and water at 65 C° for 5 min. Then a mixture containing 5X Reaction Buffer, Ribolock RNase 
Inhibitor, 10 mMdNTP Mix, M-MuLV Reverse Transcriptase added to each sample (RT+ 
samples). For the reverse transcriptase negative (RT-) controls; 1 µl of RNA of randomly 
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selected samples were taken, incubated with random hexamer and water under the same 
conditions as RT+ samples. Further same mixture without M-MuLV Reverse Transcriptase 
was added to obtain 20 µl reaction. Conditions for cDNA syntesis were  25°C for 10 min, 
42°C for 60 min and 70°C for 5 min. 
3.2.6 EndPoint Polymerase Chain Reaction 
EndPoint PCR was performed to confirm that cDNAs were free of genomic DNA. 18S 
RNA primers were used to identify gDNA contamination since it consists of only 1 exon and 
contamination would be observed in the gel electrophrases of the RT- samples. Primer 
sequence used for 18S RNA was as follows; Forward 5 
’CGTGCATTTATCAGATCAAAACCAACC-3’ and Reverse 5’-
ATGGTAGGCACGGCGACTAC-3’. 1 µl of RT+ and RT- samples and a mixture of 
OneTaq™ Quick Load® Master Mix (New England BioLabs), reverse and forward primers 
and nuclease free water were added to accomplish 25 µl reactions each. The process consisted 
of 30 cycle; 30sec. of denaturation at 94 C°, 30sec of annealing at 60 C° and 30sec of 
extension at 72 C°  with an initial denaturation step for 5 min at 94 C° and final extensin for 5 
min at 72 C°. 
3.2.7  Agarose Gel Electrophoresis 
To eliminate the possibility of gDNA contamination EndPoint PCR products were 
visiualized. 100 ml 1X TAE was mixed with 1 gr Agarose in order to obtain 1% agarose gel. 
The mixture was boiled in the microwave for a complete dissolution of agarose in 1XTAE. 
Ethidium Bromide of 5 µl was added subsequent after the agarose gel cooled down. The gel 
was poured to appropriate tank and 10 µl of ready to load samples were loaded into gel. Gene 
Ruler 50bp DNA ladder (#SM0373 Thermo Scientific Waltham, MA, USA), ready to use, 
was also loaded into gel to visiualize and confirm the size of 18S RNA product. The gel was 
run for 30 min at 120V prior to visiualization.  
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3.2.8  Quantitative Real time Polymerase Chain Reaction (qRT-PCR) 
Applied Biosystems 7500 Instrument (Applied Biosystems, Carlsbad, CA, and U.S.A) 
was used to perform qRT-PCR experiments. Each sample was run in triplicates for each target 
gene.A triplicate no template control were also prepared for each gene. Each reaction set as 20 
µl, including undiluted 2 µl cDNA of relevant sample,  10 µl 1X TaqMan Universal PCR 
Master Mix, 1 µl Taqman Gene Expression Assay (Applied Biosystems) primer-probes and 7 
µl nuclease free water. Applied Biosystems pre-made and custom primer probes designed 
with NCBI Primer –Blast Tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) were used in 
reactions. Reaction conditions were as follows; holding stage to prevent the reamplification of 
carryover PCR products by activating AmpErase UNG enzyme  at 50 C° for 2 min, holding at 
95 C° for 10 min for  the inactivation  of the  former, and 45 cycles of 15 sec.at 95 C° and 1 
min at 60 C°. GAPDH was used for normalization as an endogeneous reference control. Data 
analysis was calculated manually using ΔΔ CT Method.225 Primer probe Assay IDs - product 
catalog numbers and custom designed primer probe sequances are listed in Table 3.2 and 
Table 3.3,  respectively. 
Table 3.1 Custom Design Primer-Probe List 
Gene Exon Spanning Sequence (5’-3’) Tm °C 
TGFA-F E5-6 AAGAGACGGACTCCTGTTCACCTA 59.3 
TGFA-R E5-6 TGTGTTGGGCAGAATTCTGTTG 59.6 
TGFA-P E5-6 TTGGTGTCTGAGTCCAC 69 
ERCC1-F E9-10 GTGGGCACCTTCAGCTTTCT 58 
ERCC1-R E9-10 CCGCCACTGAATTCAGAGTCT 58 
ERCC1-P E9-10 CAGACTACACAGGCTGC 70 
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AKAP13-F E35-36 CAGCAGAAGAAGGGCACATACC 59.7 
AKAP13-R E35-36 CCTCATCAGCTTGGTATGTGGAT 59.0 
AKAP13-P E35-36 ACAGCTTGAGAGGGAA 68 
 
                                  Table3.2 Pre -Design Primer-Probe List  
Genes Assay ID Catalog No Probe Dye 
AKAP13 Hs00180747_m1 4331182 FAM 
TGFA Hs00608187_m1 4331182 FAM 
ERCC1 Hs01012158_m1 4331182 FAM 
CDX2 Hs01078080_m1 4331182 FAM 
CLDN1 Hs00221623_m1 4331182 FAM 
MAGEA1 Hs00607097_m1 4331182 FAM 
SSX1 Hs00846692_s1 4331182 FAM 
MICA Hs00792195_m1 4331182 FAM 
LIG3 Hs00242692_m1 4331182 FAM 
EWSR1 Hs01580532_g1 4331182 FAM 
GAPDH Hs00205046_m1 4331182 FAM 
 
3.2.9 Software Programs Used in This Research 
3.2.9.1  NCBI (National Center Biotechnology Information) 
mRNA sequence of all variants of all genes validated by qRT-PCR in this research 
(AKAP13, TGFα, ERCC1, CDX2, CLDN1, MAGEA1, SSX1, MICA, LIG3,   EWSR1) were 
reached from NCBI web site in FASTA format.  
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Table 3.3 Selected 10 Genes and Corresponding Links to NCBI  
Genes Link 
AKAP13 http://www.ncbi.nlm.nih.gov/gene/11214 
TGFα http://www.ncbi.nlm.nih.gov/gene/7039 
ERCC1 http://www.ncbi.nlm.nih.gov/gene/2067 
CDX2 http://www.ncbi.nlm.nih.gov/gene/1045 
CLDN1 http://www.ncbi.nlm.nih.gov/gene/9076 
MAGEA1 http://www.ncbi.nlm.nih.gov/gene/4100 
SSX1 http://www.ncbi.nlm.nih.gov/gene/6756 
MICA http://www.ncbi.nlm.nih.gov/gene/100507436 
LIG3 http://www.ncbi.nlm.nih.gov/gene/3980 
EWSR1 http://www.ncbi.nlm.nih.gov/gene/2130 
 
3.2.9.2 USCS (University of California, Santa Cruz) Blat Search Genome 
USCS Blat search tool was used to determine all cDNA sequences of each variant of each 
gene in an exon depended manner. 
(http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) 
3.2.9.3  Affymetrix NetAffyx Analysis Center 
Affymetrix NetAffyx Analysis Center, Batch Query was used to download the 
sequence of all probes of genes which were validated in this research (AKAP13, TGFA, 
ERCC1, KIR3DX1, CDX2, CLDN1, MAGEA1, SSX1, SSX4, MICA, LIG3, and EWSR1). 
3.2.9.4 Cluster 3.0 and Treeview 
Hierarchical clustering and heatmap of CT genes and TGFα in USAT analysis 
concerning Luminex data and Luminex samples were performed with cluster 3.0 and 
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treeview. To plot the trees, Euclidean distances were calculated for both genes and samples 
and average linkage method was used. In each heatmap, samples are represented according to 
their gene expression in Luminex data for the selected genes with red, black and green 
corresponding to high, intermediate and low expression, respectively. 
3.2.9.5 GraphPad Prism 5.0 
GraphPad Prism 5.0 developed by GraphPad Software Inc (La Jolla, CA, USA) was 
used to perform Pearson r correlation and survival analysis of the datas and subsequently to 
draw figures. All values considering Pearson r correlation coefficient values, linear regression 
p values and Log-rank p values were obtained using this software. 
3.2.10 Algorithms used in this Research 
3.2.10.1 Adjustment of qRT-PCR values into the Luminex Gene Expression Range 
qRT-PCR results of samples for each gene were converted into the numbers 
corresponding to gene expression values of samples for that gene. Following formula was 
used for conversion; 
NewValue = (((OldValue - OldMin) * (NewMax - NewMin)) / (OldMax - OldMin)) + 
NewMin 
 Since luminex gene expression values are log 2 transformed, all qRT-PCR results of 
all genes concerning every sample were first transformed in to log 2. Subsequently, the 
minimum qRT-PCR value for a particular gene was subtracted from a qRT-PCR value of a 
sample for that gene and multiplied with new range to old range ratio. The minimum value of 
the new range was added to the outcome, leading to adjusted value of that particular sample in 
the new range. This equation was used to calculate the adjusted values of qRT-PCR result of 
all samples for all genes.  
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3.2.10.2 Sum of Absolute Rank Difference (SARD) Analysis 
Sum of absolute rank difference analysis algorithm was developed in our laboratory 
(developer, Murat işbilen). It’s an algorithm used for estimating how differentiated a primary 
cell culture is from the day luminex gene expression profile was obtained until the validation 
experiments were performed. Principles of algorithm are grounded on the rankings of samples 
in the corresponding luminex gene expression and qRT-PCR log 2 transformed adjusted 
expression ranges for each gene underinvestigation. Rank difference of each sample is 
calculated between these rankings for each gene. Subsequently, absolute sum of each rank 
difference and sum of absolute rank difference were calculated for each sample concerning all 
genes underinvestigation. Samples were sorted from lowest to highest based on their sum of 
absolute rank differences. The sample with lowest sum of absolute rank difference was 
assumed to be least differentiated sample among all samples. Pearson correlation  and linear 
regression p values were calculated beginning with the first 3 samples and kept calculated 
with adding 1 sample at a time in SARD increasing order of samples. Numbers of significant 
genes were identified for each sample, assuming them as the last sample included for that 
particular analysis. A subset of samples was defined to be undifferentiated where the ultimate 
number of validated genes obtained. 
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4 RESULTS 
4.1 Selection of Genes to be validated as Prognostic Biomarkers  
To determine the genes which are going to be our subject in this project, we analyzed 
the normalized Luminex gene expression data of the autologous vaccinated 36 malignant 
melanoma samples with USAT (developer Murat İşbilen). USAT is composed of biostatistic 
R packages: CoxPh, Maxstat and Log-rank, and searches for a correlation between survival 
data and gene expression values.
226, 227
 Out of 121 significant genes we identified by USAT 
analysis, we selected10 genes based on their functions and possible contribution to 
melanomagenesis. Names of selected gene, corresponding affymetrix probeset IDs, hazard 
ratio (HR) values, Cox Proportional Hazard Regression (CoxPH) p values, Expression range 
of the genes, Maximally Selected Rank Statistics (Maxstat) cut-off values, Maxstat p values, 
Log-Rank p values and median survival values for high and low expression groups are 
demonstrated in Table 4.1. 
Table 4.1: Genes Significant in USAT Analyses and Corresponding Statistics 
Gene 
Name 
Affymetrix 
Probeset 
HR CoxPH 
p Value 
Expression 
Range 
Maxstat 
Cut-Point 
Maxstat 
p Value 
LogRank 
p Value 
MS for 
Low Exp. 
(Months) 
MS for 
High Exp. 
(Months) 
TGFA 205016_at 0.6651 0.0185 2.4403-9.2642 4.0735 0.0111 3.34E-06 15.35 NA 
CDX2 206387_at 0.5335 0.0076 5.456-7.2806 6.0212 0.0176 0.0009 25.70 NA 
CLDN1 218182_s_at 0.5625 0.0051 1.7968-6.3888 3.3640 0.0176 0.0009 25.70 NA 
SSX1 206626_x_at 0.6304 0.0432 2.448-5.9426 3.2411 0.0353 0.0012 27.97 NA 
MICA 205904_at 0.4962 0.0153 6.1012-8.7776 7.7953 0.0183 0.0013 24.32 NA 
MAGEA1 207325_x_at 0.6877 0.0278 4.3814-9.4401 5.5536 0.0422 0.0014 22.06 NA 
ERCC1 203719_at 0.4150 0.0196 6.5139-8.9225 8.0085 0.0071 0.0017 27.97 NA 
AKAP13 222024_s_at 1.9880 0.0153 6.3388-8.5806 7.2267 0.0481 0.0036 NA 27.97 
LIG3 207348_s_at 0.5350 0.0495 5.0414-7.2648 6.1751 0.0175 0.0062 28.66 NA 
AKAP13 221718_s_at 1.9394 0.0186 7.3045-9.8984 7.6655 0.0499 0.0086 NA 28.66 
EWSR1 210012_s_at 0.5026 0.0301 5.6571-6.8475 6.4669 0.0458 0.0154 32.61 NA 
 
44 
 
In addition, cancer testis antigens which were present in the out put captured our 
attention and we decided to study them further. . CT genes that were significantly associated 
with prognosis by USAT in this analysis are shown in Table 4.2. 
Table 4.2: CT Genes Significant in USAT Analyses and Corresponding Statistics 
 
 
Gene 
Name 
Affymetrix 
Probeset 
HR CoxPH p 
Value 
Expression 
Range 
Maxstat 
Cut-Point 
Maxstat 
p Value 
LogRank p 
Value 
MS for Low 
Exp. 
(Months) 
MS for 
High 
Exp. 
(Months) 
CTAG2 207337_at 0.5792 0.0151 5.2398-7.4981 5.8949 0.0137 0.0001 16.14 NA 
MAGEA1 207325_x_at 0.6877 0.0278 4.3814-9.4401 5.5536 0.0422 0.0014 22.06 NA 
SSX1 206626_x_at 0.6304 0.0432 2.4428-5.9426 3.2411 0.0353 0.0012 27.97 NA 
SSX4 /// 
SSX4B 
211425_x_at 0.5821 0.0176 3.1633-5.7720 3.8465 0.0079 0.0001 22.06 NA 
SSX4 /// 
SSX4B 
210394_x_at 0.5821 0.0176 3.0679-5.8641 3.6162 0.0077 0.0001 22.06 NA 
 
 
4.1.1   In silico based Analysis of CT genes and TGFα as Prognostic Markers  
Independent of USAT analysis, the distribution of these significant CT genes among 
malignant melanoma patients was assessed by performing hierarchical clustering and creating 
a heatmap image with Cluster 3 and Treeview software (Figure 4.1A). For its ranking in 
USAT as being the most significant gene, TGFα was chosen for further evaluation in terms of 
separating the patients in concert with CT genes (Figure 4.1B).  
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Figure 4.1 Heatmap and hierarchical clustering of significant CT genes and TGFα of 
Luminex data and Luminex samples. In the heatmap; red, black and green squares show that 
the corresponding sample has high, moderate and low expression for the corresponding 
probeset respectively. According to the gene tree, there are two major clusters. (A) Heatmap 
of only CT genes (B) Heatmap of CT genes with TGFα. 
According to Figure 4.1 A, it can be interpreted that samples are discriminated based 
on their Luminex data in to 2 main clusters. SSX family genes and MAGEA1 – CTAG2 are a 
subclassification for genes based on their expression range among samples. In concert with 
CT genes clusters, in figure 4.1B, it’s been demonstrated that TGFα clusters the same groups 
of samples except 1 sample M336.Expression profile of TGFα resembles both CTAG2-
MAGEA1 in high expression and SSX family genes in low expression patterns among 
samples.  
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  Survival analysis of these CT genes and TGFα based on heatmap distribution (Figure 
4.2) and Maxstat values set by USAT analysis (Figure 4.3) was performed to find out a 
possible relation with the prognosis of samples in silico.  
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Figure 4.2 Kaplan Meier curves of Heatmap data in Figure 4.1. Log –Rank p value is 
calculated for each gene, present in the figure. Blue  and red lines are corresponding to 
survival duration of samples having higher and lower expression of interested genes based on 
heatmap data, respectively. X axis indicates days and Y axis corresponds to survival 
percentage of samples when analysed based on days. Every vertical line in each colored line 
is an indicator of cencored sample.(A) Kaplan Meier curve of samples based on figure 4.1 A 
considering SSX1-MAGEA1 genes (B) Kaplan Meier curve of samples based on figure 4.1B 
considering SSX1-MAGEA1-TGFα. 
Considering heatmap distribution  of samples in terms of CT genes alone (p value, 
0.0727) and combined with TGFα (p value, 0.0398)  suggests a possible impact of  CT genes 
on prognosis only when combined with TGFα. How ever,  TGFα and  each CT gene  were 
found to  contribute the prognosis in USAT, independently.  
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Figure 4.3 Kaplan Meier curves of CT genes and TGFα based on their Luminex Expression 
profile and Maxstat cutpoint calculated using Luminex dependent-USAT analysis. Log –Rank 
p value is calculated for each gene, present in the figure.  Blue  and red lines are 
corresponding to survival duration of samples having higher and lower expression of 
interested genes, respectively. X axis indicates days and Y axis corresponds to survival 
percentage of samples when analysed based on days. Every vertical line in each colored line 
is an indicator of cencored sample. Genes demonstrated in the figure are; (A) CTAG2 (B) 
MAGEA1 (C) SSX1 (D) SSX4///SSX4B (E) TGFα. 
Based on these in silico results concerning not only the selected 10 genes but also the 
relation of CT genes with TGFα, we continued with in vitro confirmation of these genes on 
relative primary cell lines. 
4.2 Validation of First 10 sample of MM patients with qRT-PCR 
First round qRT-PCR experiments with the selected genes were performed with the 
Taqman Primer Probes (details of Primer Probes were given in Methods part). However, out 
of 11 probesets corresponding 10 genes, only 3 of them including 2 probesets of AKAP13 (p 
value 0.0299, 0.0124) and LIG3 (p value, 0.0485) were concordant with the Luminex data. 
48 
 
With a borderline p value of ERCC1 (p value, 0.0886), rest of the genes were discordant (p 
value > 0.05) with the Luminex data for 10 samples (Figure 4.4, Supplementary Figure 1). 
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Figure 4.4 Scatter plots of a sample set of selected genes analysed based on their qPCR and 
Luminex expression values from the 1st round experiments of 1st 10 samples. For each gene, 
Pearson correlation coefficient and linear regression p value are calculated and present in the 
figure. Red line corresponds to line of concordance drawn based on Pearson correlation 
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coefficient. Selected representatives genes are as follows; (A) AKAP13 (B) ERCC1 (C) 
TGFα (D) EWSR1.  
*qPCR expression range is adjusted according to Luminex expression range for each gene 
  Discorrelation of qRT-PCR experiments results and Luminex data for the 1
st
 10 
samples was further evaluated in 2nd round. None of the genes evaluated in the 2nd round 
showed concordance with Luminex data either (Figure 4.5, Supplementary Figure 2).  
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Figure 4.5 Scatter plots of a sample set of selected genes analysed based on their qPCR and 
Luminex expression values from the 2nd round of 1st 10 samples. For each gene, Pearson 
correlation coefficient and linear regression p value are calculated and present in the figure. 
Red line corresponds to line of concordance drawn based on Pearson correlation coefficient. 
Selected representatives genes are as follows; (A) LIG3 (B) CDX2 (C) EWSR1.  
*qPCR expression range is adjusted according to Luminex expression range for each gene 
To rule out any possible mistakes than can be originated from experimental procedure 
in the first 2 rounds of qRT-PCR results of 1st 10 samples Pearson correlation coefficient and 
linear regression p value were calculated with the results of 2 rounds. Out of 5 common genes 
detected in both of the rounds, the results of 3 genes demonstrated high correlation with a 
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Pearson r value greater than 0.95 (Figure 4.6). For the rest 2 genes; LIG3 demonstrated a 
border line correlation whereas, EWSR1 showed discordant results between rounds (data not 
shown).   
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Figure 4.6 Scatter plots of common genes analysed based on their qPCR results from 1st and 
2nd round of 1st 10 samples. For each gene Pearson correlation coefficient and linear 
regression p value are calculated and present in the figure. Red line corresponds to line of 
concordance drawn based on Pearson correlation coefficient. Genes are: (A) MAGEA1 (B) 
SSX1 (C) CDX2 (D) LIG3. 
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*qPCR expression range is adjusted according to Luminex expression range for each gene. 
Besides one border line result in LIG3 and an insignificant result in EWSR1 ( data not 
shown), results from both rounds have a significant Pearson r value and p value indicating 
that discordant results from both rounds for different genes might be independent of 
experimental error. 
4.3     Evaluating effect s of Custom Design and Pre Designed Primer Probes on 
Validation Experiments 
We considered that pre-designed primer probes might not match specific transcripts of 
the relevant genes which are detected in Luminex platform. To overcome this issue; we 
selected  AKAP13, ERCC1 and TGFα  as representatives of  significant, border line 
significant and insignificant genes found in 1
st
 round experiments  and specifically designed 
primers and  probes for each gene corresponding to regions interrogated by Affymetrix 
probesets, which Luminex data is based on. We downloaded all transcript variants of 
AKAP13, ERCC1 and TGFα from NCBI database and compared them to probeset sequences 
corresponding to each gene. To detect all transcript variants for each gene, primer probes 
were designed to common exons in exon spanning fashion, including the sequences amplified 
by Luminex Platform.  
 As demonstrated in Figure 4.7, we obtained similar Pearson correlation coefficient r 
values and p values for AKAP13 and TGFα when using both pre and custom design primer 
probes. On the other hand, ERRC1 displayed an inversed correlation. 
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Figure 4.7 Scatter Plots of pre design qPCR results and Luminex vs custom design qPCR 
results and Luminex expression values of 3 selected genes in the 1st 10 samples.  Correlation 
calculated with pre design qPCR results are in the first line and corresponding correlation of 
custom design qPCR results with Luminex data are in the second line for (A) AKAP13, (B) 
TGFα, (C) ERCC1. For each gene, Pearson correlation coefficient and linear regression p 
value are calculated and present in the figure. Red line corresponds to line of concordance 
drawn based on Pearson correlation coefficient.  
*qPCR expression range is adjusted according to Luminex expression range for each gene.  
2 out of 3 selected genes demonstrated a high correlation between results of pre and 
custom design experiments for the 1
st
 10 samples (Figure 4.8). Based on these results, we 
conclude that custom design and pre designed primer probes detect the same transcript with 
that identified by Luminex analysis. The discordant results from ERCC1 can be based on the 
low numbers of samples detected in the experimental procedure.  
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Figure 4.8 Scatter Plots of pre design and custom design qPCR expression values of selected 
3 genes in the 1st 10 samples. For each gene, Pearson correlation coefficient and linear 
regression p value are calculated and present in the figure. Red line corresponds to line of 
concordance drawn based on Pearson correlation coefficient. Genes are; (A) AKAP13, (B) 
TGFα, (C) ERCC1. 
  *qPCR expression range is adjusted according to Luminex expression range for each gene.  
4.4 Validation of 28 sample of MM patients with qRT-PCR 
We next increased the sample size to 28 samples and repeat tha validation experiments. 
However, we could only validate 4 out of 10 genes which are LIG3, MAGEA1, TGFα and 
ERRC1 (Figure 4.9and Supplementary Figure 3).  
 
 
54 
 
L IG 3
4 5 6 7 8
4
5
6
7
8
L u m in e x  G e n e  e x p r e s s io n  ( lo g 2 )
 *
q
P
C
R
 G
e
n
e
 E
x
p
r
e
s
s
io
n
  
(l
o
g
2
)
p  v a lu e  0 .0 0 0 8
P e a r s o n  r   0 .5 9 4 9
 T G F A
0 2 4 6 8 1 0
0
2
4
6
8
1 0
L u m in e x  G e n e  e x p r e s s io n  ( lo g 2 )
 *
q
P
C
R
 G
e
n
e
 E
x
p
r
e
s
s
io
n
  
(l
o
g
2
)
p  v a lu e  0 .0 1 4 6
P e a r s o n  r   0 .4 5 6 7
 C L D N 1
0 2 4 6 8
0
2
4
6
8
L u m in e x  G e n e  e x p r e s s io n  ( lo g 2 )
 *
q
P
C
R
 G
e
n
e
 E
x
p
r
e
s
s
io
n
  
(l
o
g
2
)
p  v a lu e  0 .8 3 9 2
P e a r s o n  r   0 .0 4 0 1
A B C
 
Figure 4.9 Scatter plots of a sample set of selected genes analysed based on their qPCR and 
Luminex expression values for 28 samples. For each gene, Pearson correlation coefficient and 
linear regression p value are calculated and present in the figure. Red line corresponds to line 
of concordance drawn based on Pearson correlation coefficient. Selected representatives 
genes are as follows; (A) LIG3, (B) TGFA; (C) CLDN1. 
*qPCR expression range is adjusted according to Luminex expression range for each gene.  
4.5 Summary of Sum of Absolute Rank Differences (SARD) based identification of 
concordance 
So far, we eliminated potential facts, such as experimental faults, inappropriate primer 
probe usage for detection and small sample size that could lead to discordants results. 
However, another potential factor could be the primary cell cultures that we use to validate 
Luminex data. Primary cell cultures are composed of all cells present in a tumour at the time 
of surgery they are obtained. In time, one subpopulation of cells present in the primary cell 
cultures may expand more and be favoured during culturing and resulting cell lines with 
altered gene expression. To asses the state of alteration of our primary cell cultures, we used 
SARD analysis, developed by Murat Isbilen. Based on SARD analysis, 7 of the samples were 
shown to be discordant in terms of qPCR and Luminex concordance (Figure 4.10).  
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 Figure 4.10 Summary of Sum of Absolute Rank Differences (SARD) analysis results. The 
samples are sorted (from top to bottom) according to total sum of absolute rank differences. 
Each blue square shows the significant correlation when the samples from top to the 
corresponding sample are included in correlation analysis. Empty squares are non-significant 
correlations. The red line shows the sample cut-off that gives the best correlation for all genes. 
Yellow bars show the number of significant genes for each sample threshold. 
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 When those 7 differentiated samples were excluded from the correlation analysis, 
both Pearson r correlation coefficient values and p values were improved significantly (Table 
4.3).  
Table 4.3 Correlation improvement between Luminex microarray data and qPCR data 
 p value Pearson r 
Genes 28 Sample 21 Sample 28 Sample 21 Sample 
LIG3 0,0012 0,0003 0,580 0,713 
CLDN1 0,8922 0,0011 0,027 0,662 
AKAP13 0,0098 0,0031 0,479 0,614 
TGFA 0,0149 0,0049 0,455 0,590 
ERCC1 0,0015 0,0064 0,570 0,575 
MAGEA1 0,0393 0,0083 0,464 0,673 
CDX2 0,6350 0,0203 0,120 0,611 
SSX1 0,1398 0,0252 0,362 0,639 
MICA 0,8931 0,7310 -0,027 0,080 
EWSR1 0,9426 0,9455 0,014 0,016 
 
A better understanding of improved correlation and election of concordants samples 
according to SARD analysis is demonstrated in CT genes dependent and independent manner 
in Figure 4.11 and Figure 4.12, respectively. Finally, we were able to demonstrate 
concordance for 8 selected genes out of 10 with the exceptions of MICA and EWSR1 
(Supplementary Figure 4). 
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Figure 4.11 Scatter Plots of validated CT genes after SARD analysis. For each gene, Pearson 
correlation coefficient and linear regression p value are calculated and present in the figure. 
Red triangles correspond to discordant samples, black dots correspond to concordant samples 
and blue line corresponds to line of concordance drawn based on Pearson r value calculated 
with the concordant samples. Genes are; (A) MAGEA1, (B) SSX1. 
*qPCR expression range is adjusted according to Luminex expression range for each gene 
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Figure 4.12 Scatter Plots of validated CT independent genes after SARD analysis.  For each 
gene, Pearson correlation coefficient and linear regression p value are calculated and present 
in the figure. Red triangles correspond to discordant samples, black dots correspond to 
concordant samples and blue line corresponds to line of concordance drawn based on Pearson 
r value calculated with the concordant samples. Genes are;  (A) CLDN1, (B) CDX2, (C) 
ERCC1, (D) LIG3, (E) AKAP13, F) TGFα. 
*qPCR expression range is adjusted according to Luminex expression range for each gene.  
4.6 Survival Analysis with Genes concordant with Luminex data 
To determine the relationship between For qRT-PCR results and survival, we used each 
gene Maxstat to determine the best threshold.for thecut point is calculated with the qRT-PCR 
results of 8 validated genes (MAGEA1, SSX1, TGFα, CLDN1, CDX2, ERCC1, LIG3, and 
AKAP13) and the survival data of the corresponding 21 concordant samples. For the 
MAGEA1, SSX1; CT genes and TGFα, the result presented in Figure 4.13 shows that we can 
validate the in silico gene-survival association of each gene identified by USAT analysis in 
the same direction with a significant Log-rank p value when tested by qRT-PCR as well. For 
the rest of the genes (CLDN1, ERCC1, LIG3), all genes have a significant Log- rank p value 
with the given cut point by Maxstat (Figure 4.14).  
 These results confirm that 7 out of 8 genes which we were able to validate, are 
significantly related with the prognosis of autologous vaccinated malignant melanoma 
patients as we proposed at the beginning based on USAT analysis. 
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Figure 4.13 Kaplan Meier curves of each validated CT genes and TGFα based on their qPCR 
results. For each gene Maxstat cut point is calculated using qPRC results of relevant genes.  
Log-rank p values of each gene are present in the figure. Blue  and red lines are corresponding 
to survival duration of samples having higher and lower expression of interested genes, 
respectively. X axis indicates days and Y axis corresponds to survival percentage of samples 
when analysed based on days. Every vertical line in each colored line is an indicator of 
cencored sample. Genes are;  (A) MAGEA1 with a Log rank p value  0.0624, (B) SSX1 with 
a Log rank p value 0.0561, (C) TGFα with a Log rank p value 0.0180. 
 
 
 
 
 
 
62 
 
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0
2 0
4 0
6 0
8 0
1 0 0
 L IG 3
D a y s
P
e
r
c
e
n
t 
s
u
r
v
iv
a
l
L IG 3  H ig h
L IG 3  L o w
p  v a lu e  0 .0 3 0 5
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0
2 0
4 0
6 0
8 0
1 0 0
C L D N 1
D a y s
P
e
r
c
e
n
t 
s
u
r
v
iv
a
l
C L D N 1  H ig h
C L D N 1  L o w
p  v a lu e  0 .0 2 8 4
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0
2 0
4 0
6 0
8 0
1 0 0
 E R C C 1
D a y s
P
e
r
c
e
n
t 
s
u
r
v
iv
a
l
E R C C 1  H ig h
E R C C 1  L o w
p  v a lu e  0 .0 1 7 4
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0
2 0
4 0
6 0
8 0
1 0 0
 A K A P 1 3
D a y s
P
e
r
c
e
n
t 
s
u
r
v
iv
a
l
A K A P 1 3  H ig h
A K A P 1 3  L o w
p  v a lu e  0 .5 8 5 1
0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0
2 0
4 0
6 0
8 0
1 0 0
 C D X 2
D a y s
P
e
r
c
e
n
t 
s
u
r
v
iv
a
l
C D X 2  H ig h
C D X 2  L o w
p  v a lu e  0 .3 4 9 9
A
E
DC
B
 
Figure 4.14 Kaplan Meier curves of each validated CT independent genes based on their 
qPCR results. For each gene Maxstat cut point is calculated using qPRC results of relevant 
genes. Log-rank p values of each gene are present in the figure. Blue  and red lines are 
corresponding to survival duration of samples having higher and lower expression of 
interested genes, respectively. X axis indicates days and Y axis corresponds to survival 
percentage of samples when analysed based on days. Every vertical line in each colored line 
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is an indicator of cencored sample. Genes are;  (A) CDX2 with a Log rank p value 0.3499,  
(B) CLDN1 with a Log rank p value 0.0284,  (C) ERCC1 with a Log rank p value 0.0174,  
(D) LIG3 with a Log rank p value 0.0305, (E) AKAP13 with a Log rank p value 0.5851. 
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5 DISCUSSION 
This study was conducted to determine mRNA based biomarkers which could identify a 
sub-population of melanoma patients who might benefit from autologous vaccination. In this 
thesis, I could validate 5 genes out of 8 genes by qRT-PCR as prognostic biomarkers, which 
were identified by a unique in silico analysis tool (USAT). These genes are; TGFα, CLDN1, 
ERCC1, LIG3, and SSX1. Besides the first 4 validated genes, SSX1 is particularly interesting 
since being a CT antigen makes it direct target of an immune response when expressed in 
tumours.
196
 
5.1  CT gene as a prognostic biomarker 
Previously, MAGEA1 is found to be highly expressed in 48% of metastatic melanomas 
compared to 16% of primary melanomas.
223
 Further, SSX1 is shown to be expressed 8% in 
various cancer types in the study conducted by Türeci et al. 
228
 In the same study, it’s shown 
that 43% of malignant melanoma samples have  SSX family gene expression, including 
SSX1-2-4. In contradiction with these literatures, this study suggests that higher expression of 
SSX1 and MAGEA1 are correlated with better survival in autologous vaccinated melanoma 
patients.  This situation might be explained with the studies of Cebon et al where he and his 
group proposed that the suppression of immune system via Tregs overcome the NY-ESO-1 
vaccination triggered immune response before the surgery. 
197
Supporting the study of Cebon 
et al., this study once more proposes that presence of CT gene expression such as MAGEA1 
and SSX1 in melanoma may not be detected by the immune system due to immune suppressor 
environment, especially Tregs, established by the tumour. Removing the tumour might 
destroy the immune-suppressive tumour microenvironment and therefore, increase the impact 
of autologous vaccination in melanoma patients.The vaccination protocol used in this cohort, 
increase the efficacy of treatment and introduce CT epitopes (MAGEA1 and SSX1)  to 
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immune system  of patients  when they are in minimal residual disease (MRD) state , thereby 
triggering immune response and   increase the  survival of patients. 
5.2 CT independent prognostic biomarkers 
TGFα can be secreted autonomously by melanoma cells; can be UVR induced or might 
be produced exogenously by keratinocytes; it can not trigger cell growth in proliferating 
melanocytes.
229
 This might be due to  two facts; (1) EGFR mediated pathway is less 
accessible  or (2)  EGFR is not the preferred as a transducer of mitogenic signals primarily.
229
 
However high expression of TGFα is characteristic of metastatic melanoma cell lines.201  
Further , TGFα is proposed to activate EGFR or EGFR/ErbB2 signalling leading migration in 
one of the  metastatic melanoma cell lines studied by Thomson et al.
230
 Activation of EGFR 
pathway is demonstrated after development of resistance to BRAF inhibitors in melanoma.
206
  
Since the samples we used are no metastatic cell cultures and they were not treated with any 
BRAF inhibitor agents leading EGFR pathway activation, increased expression of TGFα may 
trigger immune response against tumour and increase survival upon autologous vaccination. 
High expression of CLDN1, one of the EMT markers studied in this thesis, proposed to 
be related with both metastasic
210
 and primary melanomas.
213
 The issue here is the 
localization of CLDN1 when it’s upregulated.  If there are not any PKC involvement in the up 
regulation of CLDN1 and no relocalization to nucleus or cytoplasm, better outcome in the 
case of CLDN1 up regulation may be expected in primary tumours. This work supports the 
study of Cohn et al. which demonstrates that upregulation of CLDN1 expression in benign 
and primary lesions compared to metastatic melanoma, favours patients survival.
213
 High 
expression of CLDN1 validated in stage 1 and 2 patients of our cohort suggests that CLDN1 
presence in the membrane of early melanoma patients can be used as a trigger upon 
autologous vaccination. 
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ERCC1 and LIG3 are involved in nucleotide excision repair and base excision repair, 
respectively. Up-regulated ERCC1 is known to induce chemoresistance against cisplatin in 
melanoma. 
216
 Higher expression of ERCC1 suggests cisplatin resistance upon administration. 
However, LIG3 hasn’t been found to be related with prognosis or chemosensitivity in 
melanoma. Up-regulation of both enzymes is observed in patients with better overall survival. 
In this study, I was able to validate prospective biomarkers of malignant melanoma 
corresponding to better survival of patients undergoing autologous vaccination treatment. 
Autologous vaccination is a method which needs further evaluation to assess its benefits, 
particularly for escalating recognition of tumour antigens by T cell lymphocytes following 
surgery. Its impact on impeding immune surveillance and letting antigen recognition, in 
particular CT antigen recognition, is a major contribution for directly detecting and 
eliminating tumour cell thus decreasing tumour progression and increasing tumour relapse 
duration in malignant melanoma patients.Additional high TGFA expression patterns seen in 
melanoma patients are in concert with CT genes profiles and may be considered as an 
alternative prognostic biomarker to distinguish the autologous vaccination beneficial group 
for melanoma patients. 
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6 FUTURE PERSPECTIVES 
In this thesis, five genes including one cancer testis gene (SSX1) were shown to be 
related with better survival of malignant melanoma patients undergoing autologous 
vaccination. To reproduce and improve the significance of this relation, the patient’s size can 
be increased in scientifically similar projects.  In addition, malignant melanoma patients can 
be treated with demethylating agents such as 5-aza-2-deoxycytidine, known to increase the 
cancer testis gene expression, prior to surgery. This might help to increase cancer testis 
antigen specific immune responses following surgery upon autologous vaccination and thus 
increase the overall survival rate. 
Validated prospective biomarker genes in this thesis might give insights to other scientist 
and further clinicians to define appropriate treatments such as autologous vaccination centered 
immunotherapy and combined chemotherapy options for malignant melanoma patients. 
Moreover, roles of CT independent genes in the melanomagenesis and reasons to be 
immunoresponse related can be leaned and their functions can be searched in wide range. 
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Supplementary Figure 1 Scatter plots of the selected genes analysed based on their qPCR 
and Luminex expression values from the 1st round experiments of 1st 10 samples. For each 
gene, Pearson product moment correlation coefficient and linear regression p value are 
calculated and present in the figure. Red line corresponds to line of concordance drawn based 
on Pearson product moment correlation coefficient. Genes are as follows; (A) MICA, (B) 
MAGEA1, (C) LIG3, (D) SSX1, (E) CDX2, (F) CLDN1. 
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Supplementary Figure 2 Scatter plots of the selected genes analysed based on their qPCR 
and Luminex expression values from the 2nd round of 1st 10 samples. For each gene, Pearson 
correlation coefficient and linear regression p value are calculated and present in the figure. 
Red line corresponds to line of concordance drawn based on Pearson correlation coefficient. 
Genes are as follows; (A) MAGEA1, (B) SSX1. 
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Supplementary Figure 3 Scatter plots of selected genes analysed based on their qPCR and 
Luminex expression values for 28 samples. For each gene, Pearson correlation coefficient and 
linear regression p value are calculated and present in the figure. Red line corresponds to line 
of concordance drawn based on Pearson correlation coefficient. Genes are as follows; (A) 
AKAP13, (B) CDX2, (C) SSX1, (D) EWSR1, (E) MICA, (F) MAGEA1, (G) ERCC1. 
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Supplementary Figure 4 Scatter Plots of discordant genes after SARD analysis. For each 
gene, Pearson correlation coefficient and linear regression p value are calculated and present 
in the figure. Red triangles correspond to discordant samples, black dots correspond to 
concordant samples and blue line corresponds to line of concordance drawn based on Pearson 
r value calculated with the concordant samples. Genes are; (A) MICA, (B) EWSR1 
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